{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:51:33Z","timestamp":1777866693795,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>High-dose thiopental was administered in 8 children with uncontrollable\nseizures or hypoxic encephalopathy (group A) and 7 full-term neonates with neonatal\nasphyxia (group B), All of them were submitted to artificial hyperventilation to maintain\npCO(2) near 3.5 kPa. Rectal temperature was kept at about 35 \u00b0C. Thiopental was infused\nwith a rate of 2-4 mg^-1-kg^-1, with treatment lasting 32-192 h for group A (mean\n103 h), and 36-48 h for group B (mean 38.5 h). Plasma concentration-time data were\nanalysed pharmacokinetically. Thiopental elimination half-life was 14.5 h (group A) and\n20.9 h (group B). The clearance of thiopental was 0.27 liters \u00d7 h^-1 -kg\"1 (group A) and 0.32\nliters \u00d7 h^-1 \u00d7 kg-1 (group B). The volume of distribution at steady-state was 5.41 liters-kg 1\n(group A) and 8.26 liters-kg-' (group B). These results show that high-dose thiopental\npharmacokinetics is not very different for full-term newborns, children and adults. Elimination\nhalf-life and volume of distribution are changed when compared to single-dose\nstudies, while clearance is only slightly modified. The time for disappearance of thiopental\nfrom blood is also very long (2 to 5 days). These pharmacokinetic characteristics would\nbe worthy of consideration in cases where there may be prolonged use of thiopental,\nconsidering the risk of accumulation and toxicity.<\/jats:p>","DOI":"10.1159\/000457755","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:09:22Z","timestamp":1502471362000},"page":"292-300","source":"Crossref","is-referenced-by-count":7,"title":["High-Dose Thiopental Pharmacokinetics in\nBrain-Injured Children and Neonates"],"prefix":"10.1159","author":[{"given":"Jean-Louis","family":"D\u00e9marquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolland","family":"Galperine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Billeaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Brachet-Liermain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:09:46Z","timestamp":1777540186000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457755","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}